Brief: Brainstorm Cell Therapeutics Says FDA Meeting on NurOwn Provided A Clear Path For Planned Phase 3B Trial
07/12/2023 13:42
Dec 7 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS INC - MEETING PROVIDED A
CLEAR PATH
FOR PLANNED PHASE 3B TRIAL
* BRAINSTORM CELL THERAPEUTICS ANNOUNCES OUTCOME OF FDA
MEETING ON
NUROWN® IN ALS
* BRAINSTORM CELL THERAPEUTICS INC - WILL SUBMIT RELEVANT
DOCUMENTATION AS OUTLINED BY FDA TO SUPPORT SPA
Source text for Eikon: ID:nPn6Gv0lqa
Further company coverage: BCLI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview